What challenges do regulatory bodies face with these changes?
Despite the positive impact, regulatory bodies face several challenges with these changes. Ensuring the robustness and reliability of RWE, balancing the need for expedited approvals with thorough safety evaluations, and managing the complexities of adaptive trial designs are significant hurdles. Additionally, they must continuously update their frameworks to keep pace with rapidly advancing technologies and scientific discoveries in cancer treatment.
